Availability and outcomes of radiotherapy in Central Poland during the 2005-2012 period - an observational study

Chałubińska-Fendler, Justyna; Fendler, Wojciech; Spych, Michał; Łuniewska-Bury, Jolanta; Młynarski, Wojciech; Fijuth, Jacek

doi:10.1186/s12885-015-1236-7

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifteen papers presented ARUR on lung cancer, SCLC, or NSCLC, including overall ARUR (Table 2), palliative intent ARUR (Table 3), and curative intent ARUR (Table 4) (14,(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29). Measured lifetime ARUR was not available, but lifetime ARUR was estimated using the multicohort utilization table (MCUT) method in Ontario, Canada to be 52% (11).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

What is the optimal radiotherapy utilization rate for lung cancer?—a systematic review

Liu

Chan

et al. 2019

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Lung cancer is a major cause of morbidity and mortality globally. Although radiotherapy (RT) may be beneficial in the radical and/or palliative management of many lung cancer patients, it is underutilized worldwide. Population-level development of RT resources requires estimates of optimal radiotherapy utilization rates (ORUR) and actual radiotherapy utilization rate (ARUR). A systematic review of PubMed database for English-language articles from January 2009 to January 2019 was performed. Keywords included utilization, underutilization, demand, epidemiologic, benchmark, RT and cancer. Data abstracted included: study population, diagnosis, stage, year of diagnosis, timing of RT, intent of RT, ARUR, and ORUR. Eligible studies provided ARUR or ORUR for lung cancer, small cell lung cancer (SCLC), or nonsmall cell lung cancer (NSCLC). Included ARUR were based on at least 1,000 patients who were diagnosed or treated in 2009 or later. Included ORUR were based on evidence review or ARUR in 2009 or later. The initial search strategy yielded 1,627 unique abstracts. After review, 105 articles were determined appropriate for full-text review. From these, a final set of 21 articles met all inclusion criteria. In eight papers, ORUR was estimated. Estimated lifetime ORUR ranged from 61% to 82%. Methods for estimation included the evidence-based guideline model, Malthus model, and criterion-based benchmarking (CBB) model. The majority of estimates (6/8) used the evidence-based guideline model. Fifteen papers provided ARUR on lung cancer, inclusive of SCLC and NSCLC. ARUR within 9 months to 1 year of diagnosis ranged from 39% to 46%. Lifetime ARUR was an estimated 52% in Ontario, Canada. Palliative intent ARUR ranged from 12% in Central Poland to 46% in Ontario, Canada. RT is underutilized for lung cancer globally, and there is wide geographical variation in the level of underutilization.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Lung cancer is the second most common indication for RT globally (7) and has consistently been demonstrated to be the most common indication for palliative RT (18,24,25). In this systematic review, we summarized ARUR and ORUR metrics for lung cancer, and found that lung RT remains underutilized.…”

Section: Discussionmentioning

confidence: 97%